(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

The SPAC is offering up to $8.3 million worth of private placement units, committed by sponsors and independent director nominees. It also has provided 7.2 million Class B shares to initial ...

Simpson Thacher partners offer IPO tips for private companies, noting that having an independent board and the correct ...

Smithfield Foods, the world's largest pork producer, filed for an initial public offering in the US. Hong Kong-based WH Group ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised ...

A slew of companies have announced plans to list shares in Hong Kong over the next month in a further sign the city’s IPO ...

Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in ...

Jesons Industries IPO comprises of fresh issuance of equity shares worth Rs 300 crore, and an offer-for-sale of 94.6 lakh ...